BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pierra Rouviere C, Dousson CB, Tavis JE. HBV replication inhibitors. Antiviral Res 2020;179:104815. [PMID: 32380149 DOI: 10.1016/j.antiviral.2020.104815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther 2022;55:805-19. [PMID: 35224760 DOI: 10.1111/apt.16828] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tan S, Groaz E, Kalkeri R, Ptak R, Korba BE, Herdewijn P. Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. J Med Chem 2022. [PMID: 35754374 DOI: 10.1021/acs.jmedchem.2c00667] [Reference Citation Analysis]
3 Sabnis RW. Substituted Chromen-4-one Derivatives for Treating Hepatitis B Virus Infection. ACS Med Chem Lett 2021;12:322-3. [PMID: 33738053 DOI: 10.1021/acsmedchemlett.1c00076] [Reference Citation Analysis]
4 Li Q, Edwards TC, Ponzar NL, Tavis JE. A mid-throughput HBV replication inhibition assay capable of detecting ribonuclease H inhibitors. J Virol Methods 2021;292:114127. [PMID: 33766659 DOI: 10.1016/j.jviromet.2021.114127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Ma X, Li H, Gong Y, Liu F, Tong X, Zhu F, Yang X, Yang L, Zuo J. Psoralen inhibits hepatitis B viral replication by down-regulating the host transcriptional machinery of viral promoters. Virologica Sinica 2022. [DOI: 10.1016/j.virs.2022.01.027] [Reference Citation Analysis]
6 Masetti C, Pugliese N, Aghemo A, Viganò M. Safety of current antiviral drugs for chronic hepatitis B. Expert Opin Drug Saf 2022. [PMID: 35209776 DOI: 10.1080/14740338.2022.2045271] [Reference Citation Analysis]
7 Durantel D, Dousson CB, Lampertico P. Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection? J Hepatol 2021;74:1011-4. [PMID: 33715896 DOI: 10.1016/j.jhep.2021.01.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cell Signal 2020;74:109721. [PMID: 32711111 DOI: 10.1016/j.cellsig.2020.109721] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 21.5] [Reference Citation Analysis]
10 Wang Z, Chen N, Li Z, Xu G, Zhan X, Tang J, Xiao X, Bai Z. The Cytosolic DNA-Sensing cGAS-STING Pathway in Liver Diseases. Front Cell Dev Biol 2021;9:717610. [PMID: 34386500 DOI: 10.3389/fcell.2021.717610] [Reference Citation Analysis]
11 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wu Y, Ding Y, Shen C. A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus. Vaccines 2022;10:257. [DOI: 10.3390/vaccines10020257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chauhan R, Li Q, Woodson ME, Gasonoo M, Meyers MJ, Tavis JE. Efficient Inhibition of Hepatitis B Virus (HBV) Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors during Infection. Antimicrob Agents Chemother 2021;65:e0146021. [PMID: 34516242 DOI: 10.1128/AAC.01460-21] [Reference Citation Analysis]
14 Ahmad Bhat S, Islam Siddiqui Z, Ahmad Parray Z, Sultan A, Afroz M, Ali Azam S, Rahman Farooqui S, Naqui Kazim S. Naturally occurring HMGB1 inhibitor delineating the anti-hepatitis B virus mechanism of glycyrrhizin via in vitro and in silico studies. Journal of Molecular Liquids 2022;356:119029. [DOI: 10.1016/j.molliq.2022.119029] [Reference Citation Analysis]
15 Luo M, Wu S, Kalkeri R, Ptak RG, Zhou T, Van Mellaert L, Wang C, Dumbre SG, Block T, Groaz E, De Jonghe S, Li Y, Herdewijn P. Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug. J Med Chem 2020;63:13851-60. [PMID: 33191744 DOI: 10.1021/acs.jmedchem.0c01381] [Reference Citation Analysis]